Inhaled Glucocorticoids Products Return to Non-Preferred Status on September 18, 2020

Inhaled Glucocorticoids Products Return to Non-Preferred Status on September 18, 2020

FirstCare follows the Texas VDP formulary.  VDP temporarily removed the non-preferred status on April 1, 2020 in response to reported drug shortages for medications in the "Glucocorticoids, Inhaled" drug class. VDP will reverse this change in status because of sufficient availability in the market. VDP made this determination after verifying the current availability of the preferred inhaled glucocorticoid products, as well as the non-preferred inhaled glucocorticoid products through multiple sources such as ASHP, FDA, manufacturers, wholesalers, and pharmacies in various regions around Texas. Beginning September 18, 2020 the formulary will reflect the PDL status changes for all non-preferred inhaled glucocorticoid products. 

Updating to correct non-preferred status for Asmanex HFA.
For additional information and a list of preferred PDL NDCs please click here.

Send to a Friend

* Required field

Captcha The math problem above is intended to reduce spam.